VLST Corporation has conceived and reduced to practice a streamlined and efficient proprietary platform, which rapidly yields novel biologic therapeutic compositions-of-matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders.  The platform harnesses, in its most basic form, the power of evolution in the face of extremely intense natural selection.

The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies.  Moreover, the process used to identify targets also provides a clear path to developing biologic molecules that can be used for target validation studies.  The VLST approach reduces the time to clinical development and improves the likelihood of clinical success.